Table 1.
Baseline clinical characteristics in the control and cartinine groups
| Control (n = 26) |
Carnitine (n = 27) |
P | |
|---|---|---|---|
| Age, y | 64.3 ± 12.9 | 64.7 ± 12.0 | 0.892 |
| Male gender, n (%) | 14 (53.9) | 14 (51.9) | 0.887 |
| Dialysis duration, months | 141.2 ± 83.8 | 149.1 ± 105.2 | 0.763 |
| Smoking, n (%) | 9 (34.6) | 9 (33.3) | 0.923 |
| Alcohol, n (%) | 8 (30.8) | 8 (29.6) | 0.930 |
| Diabetes mellitus, n (%) | 13 (50.0) | 14 (51.9) | 0.895 |
| Systolic blood pressure before dialysis, mm Hg | 138.0 ± 12.1 | 134.0 ± 18.8 | 0.360 |
| Diastolic blood pressure before dialysis, mm Hg | 73.4 ± 10.6 | 70.5 ± 14.7 | 0.408 |
| Body mass index, kg/m2 | 21.2 ± 4.5 | 22.9 ± 4.1 | 0.170 |
| Cardiothoracic ratio, % | 53.1 ± 5.8 | 53.3 ± 4.9 | 0.922 |
| Left ventricular ejection fraction, % | 52.2 ± 11.9 | 53.2 ± 11.9 | 0.696 |
| Left ventricular mass index, g/m2 | 126.6 ± 24.8 | 126.4 ± 24.1 | 0.962 |
| Mitral early to atrial (E/A) wave velocity ratio | 1.2 ± 0.6 | 1.1 ± 0.6 | 0.875 |
| Blood hemoglobin, g/L | 106.8 ± 10.8 | 106.1 ± 9.0 | 0.800 |
| Serum albumin, g/L | 37.8 ± 2.9 | 37.9 ± 3.4 | 0892 |
| Serum calcium, mmol/L | 2.2 ± 0.1 | 2.2 ± 0.1 | 0.451 |
| Serum inorganic phosphorus, mmol/L | 1.6 ± 0.4 | 1.6 ± 0.3 | 0.810 |
| Serum total cholesterol, mmol/L | 4.1 ± 0.6 | 3.9 ± 1.1 | 0.515 |
| Serum ferritin, pmol/L | 273.9 ± 185.8 | 281.8 ± 197.7 | 0.859 |
| Serum intact parathyroid hormone, ng/L | 176.1 ± 99.3 | 133.4 ± 106.0 | 0.136 |
| Serum C-reactive protein, mg/L | 2.5 ± 2.2 | 2.2 ± 2.6 | 0.635 |
| Plasma B-type natriuretic peptide, ng/L | 291.2 ± 174.6 | 249.2 ± 229.1 | 0.457 |
| HOMA-IR, mmol/L・μU/ml | 5.9 ± 1.9 | 5.3 ± 2.3 | 0.294 |
| BMIPP summed score | 18.2 ± 6.0 | 18.9 ± 11.3 | 0.794 |
| Medications | |||
| α 1 blockers, n (%) | 2 (7.7) | 3 (11.1) | 0.677 |
| β blockers, n (%) | 17 (65.4) | 17 (63.0) | 0.858 |
| Calcium blockers, n (%) | 7 (26.9) | 7 (25.9) | 0.936 |
| RAS inhibitors, n (%) | 8 (30.8) | 9 (33.3) | 0.845 |
| Nitrates, n (%) | 3 (11.5) | 3 (11.1) | 0.962 |
| Antiplatelet drugs, n (%) | 16 (61.5) | 18 (66.7) | 0.704 |
| Anticoagulation drugs, n (%) | 3 (11.5) | 5 (18.5) | 0.487 |
| Statins, n (%) | 7 (26.9) | 7 (25.9) | 0.936 |
HOMA-IR the homeostasis model assessment index of insulin resistance, RAS renin-angiotensin system.